Physician profile
William Johnson
NPI 1568567535
$13,481.90
in general payments reported to CMS, 2019-2025
30 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,912 · 2022: $3,175 · 2023: $2,793 · 2024: $2,976 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,263 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,263.43 |
| Education | $131.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,756.08 | 2021-2025 | |
| Amgen INC. | $2,221.56 | 2021-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $1,816.47 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,399.39 | 2021-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $666.06 | 2021-2025 | Benlysta |
| Pfizer INC. | $663.60 | 2021-2025 | |
| Lilly USA, LLC | $652.07 | 2021-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $584.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $402.82 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $388.24 | 2021-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $380.88 | 2021-2024 | Acthar |
| Horizon Therapeutics Plc | $281.77 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $195.92 | 2021-2024 | Lupkynis |
| Sobi, INC | $192.07 | 2022-2024 | |
| Radius Health, INC. | $184.02 | 2021-2025 | Tymlos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $111.41 | 2023-2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $99.96 | 2021-2025 | Strensiq, Ultomiris |
| Sandoz INC. | $71.70 | 2024 | Hyrimoz |
| Organon LLC | $57.11 | 2025 | Renflexis, Hadlima |
| Teva Pharmaceuticals USA, INC. | $55.23 | 2022-2024 | Truxima, Simlandi |
| Kiniksa Pharmaceuticals, LTD. | $53.15 | 2023 | Arcalyst |
| Scilex Pharmaceuticals INC. | $40.50 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.41 | 2024-2025 | Ofev, Cyltezo |
| Genzyme Corporation | $39.21 | 2021-2023 | |
| Tersera Therapeutics LLC | $27.67 | 2025 | Quzyttir |
| Kiniksa Pharmaceuticals International, Plc | $24.99 | 2024 | Arcalyst |
| Genentech USA, INC. | $21.34 | 2024 | Actemra |
| Mylan Institutional INC. | $19.78 | 2023 | Hulio |
| Sanofi-Aventis U.S. LLC | $19.15 | 2021 | |
| Fidia Pharma USA INC. | $15.71 | 2024 | Hyalgan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.